Ideaya Biosciences Selects IDE101 as Cancer Drug Candidate for Future Clinical Trials
Ideaya Biosciences (IDYA) has officially selected IDE101 as its lead drug candidate for the treatment of cancers characterized by a lack of the CDKN2A gene. This genetic deficiency is known to contribute to uncontrolled cell growth, making it a significant target for oncology therapeutics. The company has outlined a long-term development roadmap, aiming to submit applications for regulatory approval to begin human clinical trials in the United States by 2027. This move represents a strategic step in Ideaya's pipeline expansion within the precision medicine sector.

Tickers: $IDYA
Topics: clinical development drug candidate selection oncology